Equity · Healthcare
MAZE
NASDAQMaze Therapeutics (MAZE)
The line runs 30 USD on 24 August through 31.40 USD on 20 November, on a scale from 20 to 40. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.7B USD
- EPS, diluted, year to Dec 2025
- −3.05 USD
- 52-week range
- 22 USD – 52 USD
- Avg volume
- 59.7K
- Mentions, 30 days
- 5
- Net sentiment
- +0.01
as of Nov 20, 2026
Have Maze Therapeutics (MAZE) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, Maze Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Jan 2026, show no open-market purchase.
Form 4, 90 days to 22 Nov 2026, newest reported trade 2 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Coloma Jason VChief Executive Officer | Sell | 34,501 | 1.0M USD |
| 29 Oct 2026 | Dandekar AtulCSBO | Sell | 7,500 | 241K USD |
| 01 Oct 2026 | Bernstein HaroldPresident, R&D & CMO | Sell | 16,141 | 435K USD |
| 01 Oct 2026 | Coloma Jason VChief Executive Officer | Sell | 34,501 | 932K USD |
| 29 Sep 2026 | Dandekar AtulCSBO | Sell | 7,500 | 203K USD |
| 04 Sep 2026 | Bernstein HaroldPresident, R&D & CMO | Sell | 9,705 | 255K USD |
| 03 Sep 2026 | Bernstein HaroldPresident, R&D & CMO | Sell | 5,189 | 135K USD |
| 03 Sep 2026 | Coloma Jason VChief Executive Officer | Sell | 11,411 | 297K USD |
| 03 Sep 2026 | Courtney PhillipsGC and Corp. Secretary | Sell | 2,012 | 52K USD |
| 03 Sep 2026 | Dandekar AtulCSBO | Sell | 3,243 | 84K USD |
| 02 Sep 2026 | Bernstein HaroldPresident, R&D & CMO | Sell | 5,106 | 135K USD |
| 02 Sep 2026 | Coloma Jason VChief Executive Officer | Sell | 11,227 | 297K USD |
| Sold | 17 open-market sales | 211,350 | $5.79M |
Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.
8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 29 Oct 2026 | Dandekar AtulCSBO | Option exercise | 7,500 | 78K USD |
| 01 Oct 2026 | Bernstein HaroldPresident, R&D & CMO | Option exercise | 16,141 | 168K USD |
| 29 Sep 2026 | Dandekar AtulCSBO | Option exercise | 7,500 | 78K USD |
| 01 Sep 2026 | Bernstein HaroldPresident, R&D & CMO | Option exercise | 36,141 | 168K USD |
| 01 Sep 2026 | Coloma Jason VChief Executive Officer | Option exercise | 50,000 | |
| 01 Sep 2026 | Courtney PhillipsGC and Corp. Secretary | Option exercise | 11,000 | |
| 01 Sep 2026 | Dandekar AtulCSBO | Option exercise | 12,500 | |
| 28 Aug 2026 | Dandekar AtulCSBO | Option exercise | 7,500 | 78K USD |
Which funds hold Maze Therapeutics (MAZE)?
4 of the 45 institutional funds we track reported a Maze Therapeutics position for the quarter ended 30 Sep 2026 — a combined 79.6M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 1,579,818 | 42.9M USD | +85.3% |
| Marshall Wace | Added | 1,166,108 | 31.7M USD | +27.5% |
| Two Sigma Investments | Held (±25%) | 154,383 | 4.2M USD | −20.0% |
| AQR Capital Management | Held (±25%) | 26,983 | 733K USD | −0.7% |
| Balyasny Asset Management | Exited | |||
| D. E. Shaw & Co. | Exited |
What has been filed or recorded for Maze Therapeutics (MAZE)?
The filings we hold for Maze Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 27,000 shares | 862K USD notional · 0.049% of shares out |
| 19 Oct 2026 | Fails to deliver | Shares failed to deliver | 19,693 shares | 542K USD notional · 0.036% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.79 USD | Revenue $20M |
| 30 Sep 2026 | Financials | Total assets | 511.6M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 428.5M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.76 USD | Revenue $20M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.45 USD | Revenue $20M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.05 USD | |
| 31 Dec 2025 | Financials | Net income | −131.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.05 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.66 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.77 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −1.15 USD | |
| 31 Dec 2024 | Annual report | FY 2025 reported | EPS 1.25 USD | Revenue $168M |
What is Reddit saying about Maze Therapeutics (MAZE)?
Reddit mentioned MAZE 5 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 60% read bullish, 40% bearish and 0% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Maze Therapeutics (MAZE) compare with its price?
Share ↗
Which subreddits are talking about Maze Therapeutics (MAZE)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 5 | +0.01 |
What do people ask about Maze Therapeutics (MAZE)?
What did Maze Therapeutics shares close at?31.40
Maze Therapeutics closed at 31.40 USD on 20 Nov 2026, down 3.18% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Maze Therapeutics’ market cap?1.7B
Maze Therapeutics is worth 1.7B USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.
Have Maze Therapeutics insiders bought or sold shares recently?17 sales
In the 90 days to 22 Nov 2026, Maze Therapeutics insiders reported 17 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Jan 2026, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Maze Therapeutics?4 of 45
4 of the 45 funds we track reported a Maze Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Marshall Wace and Two Sigma Investments. See Funds
When did Maze Therapeutics last report earnings?−0.79
Maze Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.79 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Maze Therapeutics?0 mentions
Maze Therapeutics was mentioned 0 times in the last 7 days across the finance subreddits we track, and 5 times over the trailing 30 days. Of the 5 mentions scored for sentiment, 60% read bullish and 40% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words